BC Week In Review | Sep 29, 2017
Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round...
BC Extra | Sep 28, 2017
Financial News

Venture roundup: Engage, Integra

On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million in a series A round led...
BC Week In Review | Jan 11, 2016
Clinical News

Staccato alprazolam: Interim Phase IIa data

Interim data from 3 epileptics with acute repetitive seizures in a double-blind, crossover, U.S. Phase IIa trial showed that single doses of 0.5, 1 and 2 mg inhaled AZ-002 led to dose-related reductions in mean...
BC Week In Review | Oct 19, 2015
Company News

Alexza drug delivery, neurology news

Alexza retained Guggenheim Securities to explore strategic options, including the sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Alexza’s Adasuve loxapine -- loxapine delivered by the...
BC Week In Review | Feb 9, 2015
Clinical News

Staccato alprazolam: Phase IIa started

Alexza began a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial to evaluate a single dose of 0.5, 1 and 2 mg inhaled Staccato in about 6 patients. Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif.  ...
BioCentury | May 6, 2013
Regulation

The patient voice

While the first meeting under FDA 's Patient-Focused Drug Development initiative focused only on one disease - chronic fatigue syndrome - it did make clear the challenges the agency faces in making use of anecdotal information to...
BioCentury | Feb 15, 2010
Finance

Faintly rewarded

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) did a round trip following Wednesday's announcement granting Biovail Corp. (TSX:BVF; NYSE:BVF) exclusive rights in the U.S. and Canada to develop and commercialize Staccato loxapine ( AZ-004 ). At its low point...
BC Innovations | Jan 28, 2010
Targets & Mechanisms

Putting anxiety to rest

Orexin 's role in narcolepsy and appetite has made receptors for the neuropeptide attractive targets for sleep and diet disorders. Now, a report from Indiana University researchers has shown that one of the brain hormone's...
BC Week In Review | Jun 22, 2009
Company News

Alexza, Symphony Allegro deal

Alexza exercised its option to acquire Symphony Allegro in a stock deal. Alexza gained the option in 2006 when it out-licensed neurology compounds to Symphony Allegro, which was formed by Symphony Capital with an investment...
BioCentury | Jun 22, 2009
Finance

Ebb & Flow

If Symphony Capital had been able to make good on the original buyback terms of its 2006 deal with Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Symphony would have doubled its money. But times being what they are,...
Items per page:
1 - 10 of 37